Devgen pharma has first-in-class small molecule kinase inhibitors for serious inflammatory
conditions. A first IND submission is expected by Q1 2009.

Promising validated pipeline in inflammation with significant upside potential

The lead compound CDE6963

• A novel, potent, highly selective ROCK I/II inhibitor exhibiting excellent efficacy in
  pre-clinical models of IBD.
• Low systemic bioavailability - with action localized to gut, which minimizes risk of
  kinase-related systemic toxicity (e.g. cardiovascular effects), as reflected in the
  good early tolerability.
• Literature supports a role for ROCK inhibition in Crohn’s disease and ulcerative
  colitis as well as in treatment of chronic obstructive pulmonary disease (COPD).
• Pre-clinical development is expected to be completed in 2008.
• Clinical development plan is in place (Clinquest).
• Start of Phase I/II clinical development is scheduled for Q1-2009 in patients with
  moderate to severe Crohn’s.